Treatment of spontaneous and chemically induced EEG paroxysms in the Fischer-344 rat with traditional antiepileptic drugs or AED+CGP 35348 polytherapy

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 27, Issue 5, 2003, Pages 847-862

  Ritchie, Glenn D ^a   Hulme, Mary E ^a   Rossi III, John ^a  

^a AIR FORCE RESEARCH LABORATORY   (United States)

Author keywords

Absence epilepsy; Aging models; Antiepileptic drugs; CGP 35348; EEG paroxysms; Fischer 344 rats; GABAA; GABAB; SWD

Indexed keywords

3 AMINOPROPYL(DIETHOXYMETHYL)PHOSPHINIC ACID; 4 AMINOBUTYRIC ACID B RECEPTOR BLOCKING AGENT; ANTICONVULSIVE AGENT; CHLORIDE CHANNEL BLOCKING AGENT; CONVULSANT AGENT; DIAZEPAM; ETHOSUXIMIDE; PHENOBARBITAL; TRIMETHYLOLPROPANE PHOSPHATE; UNCLASSIFIED DRUG; VALPROIC ACID;

ABSENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; ELECTROENCEPHALOGRAM; MALE; NONHUMAN; RAT; RAT STRAIN;

EID: 0042131938     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(03)00144-1     Document Type: Article

References (89)

1. Aamodt S.M., Shi J., Colonnese M.T., Veras W., Constantine-Paton M. Chronic NMDA exposure accelerates development of GABAergic inhibition in the superior colliculus. J. Neurophysiol. 83:2000;1580-1591.
2. Aker R.G., Ozkara C., Dervent A., Yilmaz Ona F. Enhancement of spike and wave discharges by microinjection of bicuculline into the reticular nucleus of rats with absence epilepsy. Neurosci. Lett. 322:2002;71-74.
3. Baldino F. Jr., Geller H.M. Effect of sodium valproate on hypothalamic neurons in vivo and in vitro. Brain Res. 219:1981;231-237.
4. Banjeree P.K., Snead O.C. Thalamic mediodorsal and intralaminar nuclear lesions disrupt the generation of experimentally induced generalized absence-like seizures in rats. Epilepsy Res. 17:1994;193-205.
5. Barkai E., Grossman Y., Gutnick M.J. Long-term changes in neocortical activity after chemical kindling with systemic pentylenetetrazol: an in vitro study. J. Neurophysiol. 72:1994;72-83.
6. Berkovic S.F. Childhood absence epilepsy and juvenile absence epilepsy. Wyllie E. The Treatment of Epilepsy: Principles and Practice. 1993;547-551 Lea & Febiger, Philadelphia, PA.
7. Berkovic S.F. Generalized Absence Seizures. 1993;401-410 Lea & Febiger, Philadelphia, PA.
8. B receptors. J. Neural. Transm. Suppl. 35:1992;155-177.
9. Blumenfield H., McCormick D.A. Corticothalamic inputs control the pattern of activity generated in thalamocortical networks. J. Neurosci. 20:2000;5153-5162.
10. Bruckner C., Stenkamp K., Meierkord H., Heinemann U. Epileptiform discharges induced by combined application of bicuculline and 4-aminopyridine are resistant to standard anticonvulsants in slices of rats. Neurosci. Lett. 268:1999;163-165.
11. Cain D.P. Bidirectional transfer of intracerebrally administered pentylenetetrazol and electrical kindling. Pharmacol. Biochem. Behav. 17:1982;1111-1113.
12. Camfield P., Camfield C. Epileptic syndromes in childhood: clinical features, outcomes, and treatment. Epilepsia. 43(Suppl. 3):2002;27-32.
13. Coenen A.M., Van Luijtelaar E.L. The WAG/Rij rat model for absence epilepsy: age and sex factors. Epilepsy Res. 1:1987;297-301.
14. Coenen A.M., Blezer E.H., Van Luijtelaar E.L. Effects of the GABA-uptake inhibitor tiagabine on electroencephalogram, spike-wave discharges and behavior of rats. Epilepsy Res. 21:1995;88-94.
15. Dahlin M., Knutsson E., Amark P., Nergardh A. Reduction of epileptiform activity in response to low-dose clonazepam in children with epilepsy: a randomized double-blind study. Epilepsia. 41:2000;308-315.
16. Deransart C., Vercueil L., Marescaux C., Depaulis A. The role of basal ganglia in the control of generalized absence seizures. Epilepsy Res. 32:1998;213-223.
17. de Toledo-Morrell L., Morrell F., Fleming S. Age-dependent deficits in spatial memory are related to impaired hippocampal kindling. Behav. Neurosci. 98:1984;902-907.
18. Fisher R.S. Animal models of the epilepsies. Brain Res. Brain Res. Rev. 14:1988;245-278.
19. Fueta Y., Avoli M. Pattern- and age-dependency of the antiepileptic effects induced by valproic acid in the rat hippocampus. Can. J. Physiol. Pharmacol. 69:1991;1301-1304.
20. Fukao K., Momiyama T., Ishihara K., Ujihara H., Fujita Y., Taniyama K., Serikawa T., Sasa M. Inhibition by gamma-aminobutyric acid system activation of epileptic seizures in spontaneously epileptic rats. Jpn. J. Pharmacol. 76:1998;387-396.
21. Gallitto G., Musolino R., Aliquo G., Bruno A., De Domenico P., Marlara C.E., Marabello L., Puglisi R.M., Sturniolo R., Di Perri R. Pentylenetetrazol-induced spike-wave discharges in rats: a polygraphic study. Ital. J. Neurol. Sci. 8:1987;143-150.
22. Gilbert M.E. Repeated exposure to lindane leads to behavioral sensitization and facilitates electrical kindling. Neurotoxicol. Teratol. 17:1995;131-141.
23. Gilbert M.E., Mack C.M. Seizure thresholds in kindled animals are reduced by the pesticides lindane and endosulfan. Neurotoxicol. Teratol. 17:1995;143-150.
24. Gralewicz S., Luczak C., Wiaderna D., Tomas T. Development of the age-related spontaneous spike-wave discharges in rat neocortex and exposure to a model Neurotoxin. Acta Neurobiol. Exp. (Warsz.). 55:1995;65-71.
25. Gralewicz S., Wiaderna D., Tomas T. Development of spontaneous, age-related nonconvulsive seizure electrocortical activity and radial-maze learning after exposure to m-xylene in rats. Int. J. Occup. Med. Environ. Health. 8:1995;347-360.
26. Gralewicz S., Wiaderna D., Stetkiewicz J., Tomas T. Spontaneous spike-wave discharges in rat neocortex and their relation to behaviour. Acta Neurobiol. Exp. (Warsz.). 60:2000;323-332.
27. Hamano S.I.S., Mochizuki M., Morikawa T. Phenobarbital-induced atypical absence seizure in benign childhood epilepsy with centrotemporal spikes. Seizure. 11:2002;201-204.
28. Higgins G.M., Gardier R.W. gamma-Aminobutyric acid antagonism produced by an organophosphate-containing combustion product. Toxicol. Appl. Pharmacol. 105:1990;103-112.
29. Hosford D.A., Wang Y. Utility of the lethargic (lh/lh) mouse model of absence seizures in predicting the effects of lamotrigine, vigabatrin, tiagabine, gabapentin, and topiramate against human absence seizures. Epilepsia. 38:1997;408-414.
30. B receptor activation in absence seizures of lethargic (lh/lh) mice. Science. 257:1992;398-401.
31. B receptor antagonist, in the lethargic mouse, gamma-hydroxybutyrate, and pentylenetetrazole models. J. Pharmacol. Exp. Ther. 274:1995;1399-1403.
32. Hosford D.A., Lin F.H., Kraemer D.L., Cao Z., Wang Y., Wilson J.T. Jr. Neural network of structures in which GABAB receptors regulate absence seizures in the lethargic (lh/lh) mouse model. J. Neurosci. 15:1995;7367-7376.
33. Hu R.Q., Banerjee P.K., Snead O.C. Regulation of gamma-aminobutyric acid (GABA) release in cerebral cortex in the gamma-hydroxybutyric acid (GHB) model of absence seizures in rat. Neuropharmacology. 39:2000;427-439.
34. Ishige K., Aizawa M., Ito Y., Fukuda H. Gamma-butyrolactone-induced absence-like seizures nuclear CRE- and AP-1 DNA-binding activities in mouse brain. Neuropharmacology. 35:1996;45-55.
35. Jando G., Capri D., Kandel A., Urioste R., Horvath Z., Pierre E., Vadi D., Vadacz C., Buzkaki S. Spike-and-wave epilepsy in rats: sex differences and inheritance of physiological traits. Neuroscience. 64:1995;301-317.
36. Johannessen C.U. Mechanisms of action of valproate: a commentary. Neurochem. Int. 37:2000;103-110.
37. Joy R.M. The effects of neurotoxicants on kindling and kindled seizures. Fundam. Appl. Toxicol. 5:1985;41-65.
38. Kibria E.M. Juvenile myoclonic epilepsy. J. Am. Osteopath. Assoc. 93:1993;126-128.
39. Knake S., Hamer H.M., Schomburg U., Oertel W.H., Rosenow F. Tiagabine-induced absence status in idiopathic generalized epilepsy. Seizure. 8:1999;314-317.
40. Koerner C., Danober L., Boehrer A., Marescaux C., Vergnes M. Thalamic NMDA transmission in a genetic model of absence epilepsy in rats. Epilepsy Res. 25:1996;11-19.
41. Kostopoulos G.K. Involvement of the thalamocortical system in epileptic loss of consciousness. Epilepsia. 42(Suppl. 3):2001;13-19.
42. Lerman-Sagie T., Watemberg N., Kramer U., Shahar E., Lerman P. Absence seizures aggravated by valproic acid. Epilepsia. 42:2001;941-943.
43. Loscher W. In vivo administration of valproate reduces the nerve terminal (synaptosomal) activity of GABA aminotransferase in discrete brain areas of rats. Neurosci. Lett. 160:1993;177-180.
44. Loscher W. Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Prog. Neurobiol. 58:1999;31-59.
45. Loscher W., Schmidt D. Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res. 2:1988;145-181.
46. Loscher W., Honack D., Fassbender C.P., Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsive drugs: III. Pentylenetetrazol seizure models. Epilepsy Res. 8:1991;171-189.
47. Loscher W., Cramer S., Ebert U. Differences in kindling development in seven outbred and inbred rat strains. Exp. Neurol. 154:1998;551-559.
48. Maitre M. The gamma-hydroxybutyrate signaling system in brain: organization and functional implications. Prog. Neurobiol. 51:1997;337-361.
49. Marescaux C., Vergnes M. Genetic absence epilepsy in rats from Strasbourg (GAERS). Ital. J. Neurol. Sci. 16:1995;113-118.
50. B receptor antagonists: potential new anti-absence drugs. J. Neural. Transm. (Suppl. 35):1992;179-188.
51. Mattson R.H. General principles: selection of antiepileptic drug therapy. Levy R.H., Mattson R.H., Meldrum B.S. Antiepileptic Drugs. 4th ed. 1995;123-135 Raven Press, New York, NY.
52. Mayville C., Fakhoury T., Abou-Khalil B. Absence seizures with evolution into generalized tonic-clonic activity: clinical and EEG features. Epilepsia. 41:2000;391-394.
53. Midzianovskaia I.S., Kuznetsova G.D., Coenen A.M.L., Spiridonov A.M., van Luijtelaar E.L. Electrophysiological and pharmacological characteristics of two types of spike-wave discharges in WAG/Rij rats. Brain Res. 911:2001;62-70.
54. Mikulecka A., Kresk P., Hlinak Z., Druga R., Mares P. Nonconvulsive status epilepticus in rats: impaired responsiveness to exteroceptive stimuli. Behav. Brain Res. 117:2000;29-39.
55. Musolino R., Gallitto G., De Domenico P., Bonazinga M.M., Sturniolo R., Labate C., Di Perri R. Synergistic anticonvulsant effect of valproic acid and ethosuximide on pentylenetetrazole-induced epileptic phenomena in rats. J. Int. Med. Res. 19:1991;55-62.
56. Nakamura J., Kuwana Y., Yukitoshi N. Target pharmacology of topiramate, a new antiepileptic drug. Nippon Yakurigaku Zasshi. 115:2000;53-57.
57. Niedermeyer E. Lennox-Gastaut syndrome. Clinical description and diagnosis. Adv. Exp. Med. Biol. 497:2002;61-75.
58. Nugent S., Katz M.D., Little T.E., Nugent T.I. Baclofen overdose with cardiac conduction abnormalities: case report and review of the literature. J. Toxicol. Clin. Toxicol. 24:1986;321-328.
59. Ono J., Vieth R.F., Walson P.D. Electrocorticographical observation of seizures induced by pentylenetetrazol (PTZ) injection in rats. Funct. Neurology. 5:1990;345-352.
60. Paulson G.W. Overdose of lioresal. Neurol. 26:1976;1105-1106.
61. Perucca E. Established antiepileptic drugs. Bailliere's Clin. Neurol. 5:1996;693-722.
62. Puigcerver A., van Luijtelaar E.L., Drinkenburg W.H., Coenen A.L. Effects of the GABAB antagonist CGP 35348 on sleep-wake states, behaviour, and spike-wave discharges in old rats. Brain Res. Bull. 40:1996;157-162.
63. Rossi J. III, Ritchie G.D., Buring M.S., Ademujohn C., Smith J., Morton T., Langley M. Chemical kindling of EEG epileptiform but not behavioral seizure response in two rat strains. Soc. Neurosci. Abstr. 20:1994;1459.
64. Rossi J. III, Lindsey J., Ritchie G.D., Wyman J.F., Jung A.E., Nordholm A.F. Tissue distribution, metabolism and clearance of the convulsant trimethylolpropane phosphate in rats. Drug Metab. Dispos. 26:1998;1058-1062.
65. Rossi J. III, Ritchie G.D., McInturf S., Nordholm A.F. Reduction of motor seizures in rats induced by the ethyl bicyclophosphate trimethylolpropane phosphate (TMPP). Prog. Neuropsychopharmacol. Biol. Psychiatry. 25:2001;1323-1340.
66. Russell A.C., Bekkedal M.Y., Mann T.T., Ritchie G.D., Rossi J. III, Stenger D.A., Pancrazio J.J., Andreadis J.D. Gene modulation in total brain induced by exposure to the bicyclic phosphorus ester trimethylolpropane phosphate (TMPP). Neurotoxicology. 23:2002;215-221.
67. Sawaya M.C., Horton R.W., Meldrum B.S. Effects of anticonvulsant drugs on the cerebral enzymes metabolizing GABA. Epilepsia. 16:1975;649-655.
68. Sengoku A., Kanazawa O., Kawai I., Yamaguchi T. Visual cognitive disturbance during spike-wave discharges. Epilepsia. 31:1990;47-50.
69. Shahar E., Andraus J., Sagie-Lerman T., Savitzki D. Valproic acid therapy inducing absence status evolving into generalized seizures. Pediatr. Neurol. 26:2002;402-404.
70. Shian W.J., Chi C.S. Juvenile myoclonic epilepsy. Chung Hua I. Hsueh Tsa Chih (Taipei). 53:1994;375-378.
71. Smith K.A., Bierkamper G.G. Paradoxical role of GABA in a chronic model of petit mal (absence-like) epilepsy in the rat. Eur. J. Pharmacol. 176:1990;45-55.
72. Smith K.A., Fisher R.S. The selective GABAB antagonist CGP 35348 blocks spike-wave bursts in the cholesterol synthesis rat absence epilepsy model. Brain Res. 729:1996;147-150.
73. Snead O.C. Gamma-hydroxybutyrate model of generalized absence seizures: further characterization and comparison with other absence models. Epilepsia. 29:1988;361-368.
74. Snead O.C. Pharmacological models of generalized absence seizures in rodents. J. Neural Transm. (Suppl. 35):1992;7-19.
75. B and gamma-hydroxybutyric acid receptor antagonists. Pharmacol. Biochem. Behav. 53:1996;73-79.
76. A receptor function in the gamma-hydroxybutyrate model of generalized absence seizures. Neuropharmacology. 32:1993;401-409.
77. Solderpalm B. Anticonvulsants: aspects of their mechanisms of action. Eur. J. Pain. 6(Suppl. A):2002;3-9.
78. Tan U., Marangoz C., Senyuva F. Electrocorticographic effects of topically applied ouabain, epinephrine and bicuculline. Arch. Int. Pharmacodyn. Ther. 226:1977;21-29.
79. Tani Y., Ishihara T. Changes in EEG associated with sleep-awake behavior in young adult versus aged adult Fischer-344 rats. Physiol. Behav. 44:1988;389-392.
80. Taylor M.T., Bonhaus D.W. Allosteric modulation of [(3)H] gabapentin binding by ruthenium red. Neuropharmacology. 39:2000;1267-1273.
81. Van Luijteleer E.L., Van der Werd S.J., Vossen J.M., Coenen A.M. Arousal, performance and absence seizures in rats. Electroencephal. Clin. Neurophysiol. 79:1991;430-434.
82. Van Luijteleer E.L., de Bruin S.F., Declerck A.C., Renier W.O., Vossen J.M., Coenen A.M. Disturbances in time estimation during absence seizures in children. Epilepsy Res. 9:1991;148-153.
83. Vergnes M., Marescaux C., Depaulis A., Micheletti G., Warter J.M. Ontogeny of spontaneous petit mal-like seizures in Wistar rats. Brain Res. 395:1986;85-87.
84. Vergnes M., Boehrer A., Reibel S., Simler S., Marescaux C. Selective susceptibility to inhibitors of GABA synthesis and antagonists of GABA(A) receptor in rats with genetic absence epilepsy. Exp. Neurol. 161:2000;714-723.
85. Vuilleumier P., Assal F., Blanke O., Jallon P. Distinct behavioral and EEG topographic correlates of loss of consciousness in absences. Epilepsia. 41:2000;687-693.
86. Wiaderna D., Gralewicz S., Tomas T. Behavioural changes following a four-week inhalation exposure to hemimellitene (1,2,3-trimethylbenzene) in rats. Int. J. Occup. Med. Environ. Health. 11:1998;319-334.
87. Wirrell E.C., Camfield C.S., Camfield P.R., Gordon K.E., Doole J.M. Long-term prognosis of typical childhood absence epilepsy: remission or progression to juvenile myoclonic epilepsy. Neurology. 47:1996;912-918.
88. Yamada N., Morimoto K., Otsuki K. Recent progress in development of psychotropic drugs (4) - anticonvulsants: an overview on the mechanisms of action. Nihon Shinkei Seishin Yakurigaku Zasshi. 16:1996;151-159.
89. Yuen A.W. Lamotrigine: a review of antiepileptic efficacy. Epilepsia. 5(Suppl. 35):1994;33-36.